Psychosis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Psychosis – Pipeline Review, H2 2016’, provides an overview of the Psychosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psychosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psychosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Psychosis

The report reviews pipeline therapeutics for Psychosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Psychosis therapeutics and enlists all their major and minor projects

The report assesses Psychosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Psychosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Psychosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Psychosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acadia Pharmaceuticals Inc.

Addex Therapeutics Ltd

Evotec AG

Gabather AB

Glenmark Pharmaceuticals Ltd.

Heptares Therapeutics Limited

Integrative Research Laboratories Sweden AB

Merck & Co., Inc.

Newron Pharmaceuticals S.p.A.

Reviva Pharmaceuticals Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Psychosis Overview 8

Therapeutics Development 9

Pipeline Products for Psychosis - Overview 9

Psychosis - Therapeutics under Development by Companies 10

Psychosis - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Psychosis - Products under Development by Companies 13

Psychosis - Companies Involved in Therapeutics Development 14

Acadia Pharmaceuticals Inc. 14

Addex Therapeutics Ltd 15

Evotec AG 16

Gabather AB 17

Glenmark Pharmaceuticals Ltd. 18

Heptares Therapeutics Limited 19

Integrative Research Laboratories Sweden AB 20

Merck & Co., Inc. 21

Newron Pharmaceuticals S.p.A. 22

Reviva Pharmaceuticals Inc. 23

Sumitomo Dainippon Pharma Co., Ltd. 24

Sunovion Pharmaceuticals Inc. 25

Psychosis - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 32

Drug Profiles 33

ADX-88178 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

CB-0306 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

evenamide - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

GT-001 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

GT-002 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

GT-004 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

GT-006 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

HUF-101 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

IRL-790 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

pimavanserin tartrate - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

RP-5063 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

SEP-39 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecule for Psychosis - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Psychosis - Dormant Projects 60

Psychosis - Discontinued Products 61

Psychosis - Product Development Milestones 62

Featured News & Press Releases 62

May 31, 2016: ACADIA Pharmaceuticals Announces NUPLAZID (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis 62

Apr 29, 2016: FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease 62

Mar 29, 2016: FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID(Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks 63

Jan 29, 2016: ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID(Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis 64

Nov 17, 2014: Heptares First-In-Class Selective Muscarinic Agonists Chosen As One Of Top Neuroscience Projects To Watch 64

Sep 02, 2014: Acadia Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZIDâ„¢ (Pimavanserin) for Parkinson’s Disease Psychosis 65

Aug 28, 2014: ACADIA Pharmaceuticals Announces Trade Name NUPLAZID for Pimavanserin 65

Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting 66

Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis 67

May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 67

Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 68

Appendix 69

Methodology 69

Coverage 69

Secondary Research 69

Primary Research 69

Expert Panel Validation 69

Contact Us 69

Disclaimer 70

List of Tables

List of Tables

Number of Products under Development for Psychosis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Psychosis – Pipeline by Acadia Pharmaceuticals Inc., H2 2016 14

Psychosis – Pipeline by Addex Therapeutics Ltd, H2 2016 15

Psychosis – Pipeline by Evotec AG, H2 2016 16

Psychosis – Pipeline by Gabather AB, H2 2016 17

Psychosis – Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 18

Psychosis – Pipeline by Heptares Therapeutics Limited, H2 2016 19

Psychosis – Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 20

Psychosis – Pipeline by Merck & Co., Inc., H2 2016 21

Psychosis – Pipeline by Newron Pharmaceuticals S.p.A., H2 2016 22

Psychosis – Pipeline by Reviva Pharmaceuticals Inc., H2 2016 23

Psychosis – Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 24

Psychosis – Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Stage and Target, H2 2016 28

Number of Products by Stage and Mechanism of Action, H2 2016 30

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 32

Psychosis – Dormant Projects, H2 2016 60

Psychosis – Discontinued Products, H2 2016 61

List of Figures

List of Figures

Number of Products under Development for Psychosis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Top 10 Targets, H2 2016 27

Number of Products by Stage and Top 10 Targets, H2 2016 27

Number of Products by Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 31

Number of Products by Stage and Molecule Types, H2 2016 32

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports